کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11015613 | 1782694 | 2018 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ECMTissue inhibitors of MMPsTIMPsVEGFRMmpsRegorafenibFGFRHCC - HCCRTKs - RTK هاInvasion - تهاجمSorafenib - سورفانیبVascular endothelial growth factor - فاکتور رشد اندوتلیال عروقیVascular Endothelial Growth Factor (VEGF) - فاکتور رشد اندوتلیال عروقی (VEGF)Extracellular matrix - ماتریکس خارج سلولیMetastasis - متاستاز Matrix metalloproteinases - متالوپروتئیناز ماتریکسHepatocellular carcinoma - کارسینوم هپاتوسلولار(کارسینوم سلولهای استخوانی)Platelet-derived growth factor receptor alpha - گیرنده آلفای فاکتور رشد حاصل از پلاکتreceptor tyrosine kinases - گیرنده تیروزین کینازvascular endothelial growth factor receptor - گیرنده فاکتور رشد اندوتلیال عروقیFibroblast growth factor receptors - گیرنده های فیبروبلاست فاکتور رشد
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
زیست شیمی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
To investigate the effect of multi-kinase kinase inhibitors (sorafenib; regorafenib; lenvatinib) on the invasion and metastasis of human hepatocellular carcinoma (HCC) cells, and the outcome of this effect on the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), yet unclarified. Cells were subjected to four different treatments: blank control group, sorafenib (10â¯Î¼mol/L) treatment group, regorafenib (20â¯mmol/L) treatment group, and lenvatinib (4â¯Î¼mol/L) treatment group. Anti-invasion and anti-metastasis effects were tested using the wound-healing assay and transwell invasion assay. Real-time PCR and Western blot analyses were used to determine the impact of sorafenib, regorafenib, and lenvatinib on the gene expression of MMPs and TIMPs in the two HCC lines (Hep3B and SMMC-7721). Results from the wound-healing and transwell invasion assays showed the three tested anti-cancer drugs to have a significant inhibitory effect on the metastasis and invasion of HCC cells. Real-time PCR and western blot analyses revealed that sorafenib down-regulated the expressions of MMP-7,10,16 and up-regulated those of TIMP-1,3,4, regorafenib down-regulated the expression of MMP-1 and up-regulated TIMP-3 gene expression, and lenvatinib down-regulated the expressions of MMP-1,2,7,9,10,16 and up-regulated those of TIMP-1,3,4. However, these three targeted anti-cancer drugs seem to have no significant regulatory effect on the expressions of other MMPs and TIMPs family genes. In conclusion, sorafenib, regorafenib, and lenvatinib inhibit the invasion and metastasis of HCC cells by regulating MMPs/TIMPs expression levels.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biochemical and Biophysical Research Communications - Volume 504, Issue 4, 12 October 2018, Pages 878-884
Journal: Biochemical and Biophysical Research Communications - Volume 504, Issue 4, 12 October 2018, Pages 878-884
نویسندگان
Xiao-xiao He, Liang-liang Shi, Meng-jun Qiu, Qiu-ting Li, Meng-meng Wang, Zhi-fan Xiong, Sheng-li Yang,